Matthew Jenkin | Newton

Matt is a member of Newton’s equity research team. Matt is responsible for covering the healthcare sector, specifically biopharmaceutical and medical-technology companies, and managing portfolios in the Smart Cures Innovation strategy.

Joined industry: 2000
Joined the Group: 2015

Topics of expertise

Matt joined Newton in September 2021, following the integration of Mellon Investments Corporation’s equity and multi-asset capabilities into the Newton Investment Management Group. Before joining Newton, Matt was a senior research analyst at Mellon Investments Corporation and The Boston Company Asset Management (both BNY Mellon group companies).

Prior to joining BNY Mellon, Matt served as a portfolio manager and analyst covering the healthcare sector at Balyasny Asset Management. Prior to that, he managed global long/short equity healthcare hedge funds and covered the pharmaceuticals, biotechnology and healthcare services industries at Lehman Brothers/Barclays Capital. Prior to joining the investment industry, Matt was a senior research scientist at SmithKline Beecham.

Matt has a BS in Biology from Tulane University and an MBA from New York University.

Insights from Matthew Jenkin

Medical Technology: From Bust to Boom?

Medical Technology: From Bust to Boom?

The industry appears ready for an upswing.

July 18, 2023 Matthew Jenkin

Road, Freeway, Tunnel

Operation Warp Speed for Cell and Gene Technologies

How is the US Food and Drug Administration fast-tracking genetic medicines?

May 26, 2023 Matthew Jenkin, Stefanie Rintoul

Investing in an era of unusual change

Genetic Medicines: A Two-Decade Revolution in Health Care?

Why we view genetic medicines as one of the most exciting developments in the health-care sector today.

September 13, 2022 Matthew Jenkin

See all insights

This is a financial promotion. Issued by Newton Investment Management Limited, The Bank of New York Mellon Centre, 160 Queen Victoria Street, London, EC4V 4LA. Registered in England No. 01371973. Newton Investment Management is authorised and regulated by the Financial Conduct Authority, 12 Endeavour Square, London, E20 1JN and is a subsidiary of The Bank of New York Mellon Corporation. Newton is registered with the SEC as an investment adviser under the Investment Advisers Act of 1940. Newton’s investment business is described in Form ADV, Part 1 and 2, which can be obtained from the SEC.gov website or obtained upon request. Material in this publication is for general information only. The opinions expressed in this document are those of Newton and should not be construed as investment advice or recommendations for any purchase or sale of any specific security or commodity. Certain information contained herein is based on outside sources believed to be reliable, but its accuracy is not guaranteed. You should consult your advisor to determine whether any particular investment strategy is appropriate. This material is for institutional investors only. Past performance is not a guide to future performance. Your capital may be at risk. The value of investments and the income from them can fall as well as rise and investors may not get back the original amount invested. Unless you are notified to the contrary, the products and services mentioned are not insured by the FDIC (or by any governmental entity) and are not guaranteed by or obligations of The Bank of New York or any of its affiliates. The Bank of New York assumes no responsibility for the accuracy or completeness of the above data and disclaims all expressed or implied warranties in connection therewith. © 2006 The Bank of New York Company, Inc. All rights reserved. Securities in Canada are offered through BNY Mellon Asset Management Canada Ltd. (MAML), registered as a Portfolio Manager and Exempt Market Dealer in all provinces and territories of Canada and as an Investment Fund Manager and Commodity Trading Manager in Ontario. MAML is an indirect wholly owned subsidiary of The Bank of New York Mellon Corporation and is an affiliate of Newton’s. Unless otherwise indicated, all financial data is shown in U.S. dollars. This document has been provided in Canada by MAML for use with institutional investors only and may not be redistributed without authorization.